Company News For Jan 6, 2020

Zacks Equity Research Published on January 06, 2020

Shares of Can-Fite BioPharma Ltd. (CANF - Free Report) surged 12.8% after the company announced pre-clinical data from the Hadassah Medical Center lab reveal that Namodenoson induces weight loss.
Shares of Lamb Weston Holdings, Inc. (LW - Free Report) gained 11.3% after the company delivered Q2 fiscal 2020 adjusted earnings of 95 cents per share, surpassing the Zacks Consensus Estimate of 85 cents.
Shares of Incyte Corporation (INCY - Free Report) declined 9.4% after the company revealed that Itacitinib did not statistically improve overall response rate or non-relapse mortality compared to placebo in Phase 3 study.
Shares of Novan, Inc. declined 73.1% after the company revealed top-line efficacy results from the Phase 3 B-SIMPLE program that evaluated SB206 for the treatment of molluscum contagiosum, which disclosed that statistical significance was not achieved for the primary endpoint in either B-SIMPLE1 or B-SIMPLE2.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.